Related Experiment Video
Updated: Apr 12, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Prevention and reversal of type 1 diabetes--past challenges and future opportunities
1Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL jskyler@miami.edu.
Abstract:
Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize-potentially even reverse-the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in β-cell function compared with randomized control groups, while others have failed to slow the decline in β-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.
Insights
Clinical trials for type 1 diabetes (T1D) prevention and treatment have not yet succeeded. Future research must address challenges to improve outcomes for those at risk or newly diagnosed with T1D.
Area of Science:
- Immunology
- Endocrinology
- Clinical Medicine
Background:
- Type 1 diabetes (T1D) is an autoimmune disease with no cure.
- Numerous clinical trials have aimed to prevent or reverse T1D over the last 30 years.
- Current prevention strategies have not delayed or prevented T1D onset.
Purpose of the Study:
- To review the history of T1D prevention and treatment trials.
- To identify challenges encountered in T1D interdiction efforts.
- To propose future research directions for T1D intervention.
Main Methods:
- Review of clinical trial data and outcomes.
- Analysis of challenges in T1D pathogenesis and intervention.
- Synthesis of findings to outline future opportunities.
Main Results:
- No T1D prevention trials have successfully delayed or prevented the disease.
- Intervention trials in recent-onset T1D have yielded mixed results.
- Some trials showed transient improvements in beta-cell function, while others failed to slow disease progression.
Conclusions:
- Significant challenges persist in preventing and treating type 1 diabetes.
- Past trial outcomes highlight the need for novel strategies.
- Future research should focus on overcoming existing hurdles to improve T1D management and outcomes.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes: Symptoms, Diagnosis, and Complications
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

